An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by the American public, while confidence in other vaccines ...

Eight-point-eight percent decrease seen in volume of patient-initiated medical advice message threads in six months after implementation ...

Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Antiretroviral therapy recommended for all individuals with HIV; recommendations provided for those with specific clinical circumstances ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

Patients treated with OAV101 IT showed an increase from baseline in HFMSE total score compared with sham control. Topline data were announced from a phase 3 trial evaluating intrathecal ...